Research programme: neuroimmunophilin ligands - MGI Pharma

Drug Profile

Research programme: neuroimmunophilin ligands - MGI Pharma

Alternative Names: FKBP neuroimmunophilin ligands - MGI Pharma; Immunophilin ligands - MGI Pharma; NIL programme - MGI Pharma

Latest Information Update: 03 Sep 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johns Hopkins University
  • Class
  • Mechanism of Action Immunophilin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alopecia; Cognition disorders; Deafness; Erectile dysfunction; Neurological disorders

Most Recent Events

  • 03 Sep 2007 Discontinued - Preclinical for Alopecia in USA (PO)
  • 03 Sep 2007 Discontinued - Preclinical for Cognition disorders in USA (PO)
  • 03 Sep 2007 Discontinued - Preclinical for Deafness in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top